GlassScriptPhysician profile
Julie Strebel
NPI 1013967298
$3,564.33
in general payments reported to CMS, 2019-2025
28 companies · $713 in 2025
The $713 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $75.94 · 2021: $418 · 2022: $321 · 2023: $857 · 2024: $652 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.28 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $448.91 | 2021-2025 | |
| Astellas Pharma US INC | $413.35 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $357.06 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $326.73 | 2024-2025 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $216.95 | 2019-2025 | |
| Amgen INC. | $191.48 | 2019-2024 | Prolia, Evenity |
| Minerva Surgical, INC | $170.50 | 2023 | |
| Pfizer INC. | $163.38 | 2019-2025 | |
| Therapeuticsmd, INC. | $156.34 | 2019-2021 | |
| Millicent US INC | $155.52 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Hologic Sales and Service, LLC | $147.22 | 2019-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Avion Pharmaceuticals | $125.92 | 2019-2023 | Balcoltra |
| Agile Therapeutics, INC. | $115.35 | 2021-2024 | Twirla |
| Meditrina | $95.98 | 2022-2024 | |
| Exeltis, USA INC. | $84.41 | 2021-2025 | Slynd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $76.42 | 2022-2025 | Truclear, Ligasure |
| Gynesonics, INC. | $43.43 | 2021 | |
| Merck Sharp & Dohme LLC | $42.27 | 2019-2023 | Gardasil 9 |
| Organon LLC | $41.84 | 2021-2025 | Nexplanon |
| Coopersurgical, INC. | $36.98 | 2024-2025 | Paragard T 380a, Endosee |
| Evofem Biosciences, INC. | $28.80 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $21.75 | 2025 | Exparel |
| Vertical Pharmaceuticals, LLC | $21.26 | 2019 | |
| Mylan Pharmaceuticals INC. | $20.64 | 2021 | |
| Dexcom, INC. | $20.38 | 2024 | Dexcom G6 Transmitter |
| Avanos Medical | $17.95 | 2019 | |
| Radius Health, INC. | $12.37 | 2021 | |
| Allergan, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Strebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.